Call Options

7 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q4 2022

Feb 14, 2023

BUY
$19.96 - $28.22 $1,996 - $2,822
100 Added 0.45%
22,300 $5,000
Q3 2022

Nov 14, 2022

BUY
$18.26 - $31.1 $125,994 - $214,590
6,900 Added 45.1%
22,200 $9,000
Q2 2022

Aug 12, 2022

BUY
$19.08 - $26.7 $49,607 - $69,420
2,600 Added 20.47%
15,300 $20,000
Q1 2022

May 12, 2022

BUY
$21.19 - $40.01 $23,309 - $44,011
1,100 Added 9.48%
12,700 $15,000
Q4 2021

Feb 14, 2022

BUY
$30.97 - $54.03 $359,252 - $626,748
11,600 New
11,600 $50,000
Q1 2021

May 14, 2021

SELL
$26.34 - $83.07 $287,106 - $905,462
-10,900 Closed
0 $0
Q4 2020

Feb 16, 2021

BUY
$25.51 - $43.38 $278,059 - $472,842
10,900 New
10,900 $8,000

Others Institutions Holding VIR

About Vir Biotechnology, Inc.


  • Ticker VIR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 132,638,000
  • Market Cap $1.4B
  • Description
  • Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 fo...
More about VIR
Track This Portfolio

Track Hap Trading, LLC Portfolio

Follow Hap Trading, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hap Trading, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Hap Trading, LLC with notifications on news.